Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Autor: Morfouace, M, Novello, S, Stevovic, A, Dooms, C, Janzic, U, Berghmans, T, Dziadziuszko, R, Gorlia, T, Felip, E, Paz-Ares, L, Mazieres, J, O'Brien, M, Bironzo, P, Vansteenkiste, J, Lacroix, L, Dingemans, AC, Golfinopoulos, V, Besse, B

Publikováno v: Scientia
Scientific Reports, 12(1):8342. Nature Publishing Group
Scientific reports, vol. 12, pp. 1-11, 2022.

Cancer screening; Non-small-cell lung cancer Cribado de cáncer; Cáncer de pulmón de células no pequeñas Cribratge de càncer; Càncer de pulmó no de cèl·lules petites Access to a comprehensive molecular alteration screening is patchy in Europ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::983fcf2c36c091b32f8d94bfdb198f61
https://hdl.handle.net/11351/8038

18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.

Autor: van Loon J (AUTHOR), Grutters JPC (AUTHOR), Wanders R (AUTHOR), Boersma L (AUTHOR), Dingemans AC (AUTHOR), Bootsma G (AUTHOR), Geraedts W (AUTHOR), Pitz C (AUTHOR), Simons J (AUTHOR), Brans B (AUTHOR), Snoep G (AUTHOR), Hochstenbag M (AUTHOR), Lambin P (AUTHOR), De Ruysscher D (AUTHOR)

Publikováno v: European Journal of Cancer. Jan2010, Vol. 46 Issue 1, p110-119. 10p.

Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.

Autor: Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Felip E; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Barcelona, Spain., Korantzis I; Department of Medical Oncology, Saint Loukas Hospital, Thessaloniki, Greece., Ohashi K; Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan., Majem M; Hospital de la Santa Creu i Sant Pau, Spain., Juan-Vidal O; Barcelona, Hospital Universitari i Politecnic La Fe, Valencia, Spain., Handzhiev S; Klinische Abteilung für Pneumologie, Universitätsklinikum Krems, Krems, Austria., Izumi H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Lee JS; Seoul National University Bundang Hospital, Seongnam, South Korea., Dziadziuszko R; Department of Oncology & Radiotherapy & Early Phase Clinical Trials Center, Medical University of Gdansk, Gdansk, Poland., Wolf J; Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany., Blackhall F; Christie NHS Foundation Trust & University of Manchester, Manchester, United Kingdom., Reck M; Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany., Alvarez JB; West Virginia University Health Sciences Center, Morgantown, WV, USA., Hummel HD; Translational Oncology-Early Clinical Trial Unit, Comprehensive Cancer Center Mainfranken & Bavarian Cancer Research Center, Universitätsklinikum Würzburg, Würzburg, Germany., Dingemans AC; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Sands J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Akamatsu H; Wakayama Medical University Hospital, Wakayama, Japan., Owonikoko TK; Division of Hematology-Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Ramalingam SS; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Borghaei H; Fox Chase Cancer Center, Philadelphia, PA, USA., Johnson ML; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA., Huang S; Amgen, Thousand Oaks, CA, USA., Mukherjee S; Amgen, Thousand Oaks, CA, USA., Minocha M; Amgen, Thousand Oaks, CA, USA., Jiang T; Amgen, Thousand Oaks, CA, USA., Martinez P; Amgen, Thousand Oaks, CA, USA., Anderson ES; Amgen, Thousand Oaks, CA, USA., Paz-Ares L; Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University & Ciberonc, Madrid, Spain.

Publikováno v: Future oncology (London, England) [Future Oncol] 2024 Nov 12, pp. 1-10. Date of Electronic Publication: 2024 Nov 12.

A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".

Autor: Ernst SM; Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., von der Thüsen JH; Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Dubbink HJ; Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Dingemans AC; Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. Electronic address: a.dingemans@erasmusmc.nl.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Sep; Vol. 19 (9), pp. e44-e45.

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Autor: Gangaev A; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands., van Sleen Y; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands., Brandhorst N; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Hoefakker K; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Prajapati B; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands., Singh A; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands., Boerma A; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands., van der Heiden M; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center (MC)-Cancer Institute, Rotterdam, Netherlands., Hiltermann TJN; Department of Pulmonary Diseases, University Medical Centre Groningen, Groningen, Netherlands., GeurtsvanKessel CH; Department of Viroscience, Erasmus Medical Center (MC) Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Dingemans AC; Department of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, Netherlands., Smit EF; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Haanen JBAG; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands., van Baarle D; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, Netherlands.; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Utrecht, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Aug 27; Vol. 15, pp. 1447555. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).